Oxford Sciences Innovation is a science business builder that works with academics to commercialise research and build companies based on Oxford science.
Portfolio
11
companies
AUM
£600M
under management
Mind Foundry
Mind Foundry develops artificial intelligence platforms designed to help organisations make better operational decisions.
Mixergy
Smart hot water storage and home energy solutions provider.
MoA Technology
MoA Technology develops next-generation herbicides to combat global weed resistance.
ORCA Computing
ORCA Computing develops full-stack photonic quantum computing systems.
Omega Crop
Omega Crop builds remote-sensing and modelling technology to help farms predict yields and diagnose crop losses.
Orbit Discovery
Orbit Discovery develops proprietary screening platforms for candidate peptide therapeutics.
Oxford Endovascular
Oxford Endovascular develops origami-inspired medical devices for brain aneurysm treatment.
PQShield
PQShield builds quantum-resistant cryptographic solutions for the global technology supply chain.
Ultromics
Ultromics develops artificial intelligence tools to detect hidden heart disease.
YASA
YASA manufactures axial flux electric motors and controllers for electric vehicles.
Zegami
Zegami provides visual data exploration software that helps businesses unlock insights from complex datasets.
Charles Conn
CEO
Charles brings investment, executive, and board experience from roles including CEO of Oxford Sciences Innovation, co-founder of Monograph Capital, and chair of Patagonia.
LinkedIn
Martin Fiennes
Principal
Martin advises on deep tech at Oxford Science Enterprises, having previously been a principal at Oxford Sciences Innovation. He also holds non-executive directorships across several companies.
LinkedInWill Goodlad
Principal
Nick Dixon-Clegg
Principal
Matt Arnold
Principal
Matt brings financial and investment experience from roles at Mind Foundry, Oxford Science Enterprises, and Goldman Sachs. He serves as chief financial officer at Fractile.
LinkedInThe Series B round was led by the Blue Venture Fund to accelerate the deployment of artificial intelligence in echocardiography.
"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,"
The financing round was led by Oxford Sciences Innovation to support the company in expanding its peptide discovery operations.
"Orbit’s team has the right combination of scientific rigor and novel peptide technologies to lead a new generation of drug development, and we look forward to partnering with the team to advance their mission,"
Oxford Sciences Innovation led the seed investment, which will fund commercialisation and technological advancement.
"The world must create 70% more food by 2050 in a sustainable way. We need to double production, improve efficiencies on existing farmland, and avoid destroying more rainforests. At Omega Crop we can monitor and evaluate vast tracts of farmland, diagnosing crop loss events at scale and enable targeted interventions that will help feed our growing world."
The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.
"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
The University of Oxford spinout secured £10.4m from backers including Parkwalk Advisors and Oxford Sciences Innovation to expand its presence in the insurance sector.
"There are some technologies that can change a small part of the insurance value chain, but there are no technology companies that can help insurers transform the entire insurance operation. Therefore, we had been seeking a reliable partner with first-class technology in order to jointly develop such solutions across the insurance value chain."
